Pazopanib Hydrochloride CAS 635702-64-6 Mimo>99.0% (HPLC) Aworan Ifihan Ile-iṣẹ API

Pazopanib Hydrochloride CAS 635702-64-6 Mimọ>99.0% (HPLC) API Factory

Apejuwe kukuru:

Orukọ Kemikali: Pazopanib Hydrochloride

CAS: 635702-64-6

Irisi: Funfun si Iyẹfun Yellow Die-die

Mimọ:> 99.0% (HPLC)

Inhibitor olugba Tyrosine kinase fun itọju to ti ni ilọsiwaju carcinoma sẹẹli kidirin tabi sarcoma asọ asọ ti ilọsiwaju

API Didara Giga, Iṣelọpọ Iṣowo

Inquiry: alvin@ruifuchem.com

Fi imeeli ranṣẹ si wa

Alaye ọja

Jẹmọ Products

ọja Tags

Apejuwe:

Ipese Olupese pẹlu Iwa-mimọ giga ati Didara Idurosinsin
Orukọ Kemikali: Pazopanib Hydrochloride
CAS: 635702-64-6
Tyrosine kinase receptor inhibitor fun itọju to ti ni ilọsiwaju kidirin cell carcinoma tabi sarcoma asọ ti o ni ilọsiwaju ti o ti gba chemotherapy ṣaaju.
API Didara Giga, Iṣelọpọ Iṣowo

Kemikali Properties:

Orukọ Kemikali	Pazopanib Hydrochloride
Awọn itumọ ọrọ sisọ	Pazopanib HCl;GW786034 HCl;Votrient;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride
Nọmba CAS	635702-64-6
NỌMBA CAT	RF-API93
Iṣura Ipo	Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn ọgọọgọrun Kilogram
Fọọmu Molecular	C21H23N7O2S.ClH
Òṣuwọn Molikula	473.987
Solubility	DMSO
Ojuami Iyo	300.0 ~ 304.0 ℃
Brand	Ruifu Kemikali

Awọn pato:

Nkan	Awọn pato
Ifarahan	Funfun to Die-die Yellow Powder
Idanimọ	Iwọn gbigba infurarẹẹdi ti ayẹwo idanwo jẹ ibamu pẹlu ti boṣewa
Aloku lori Iginisonu	≤0.50%
Eyikeyi Olukuluku aimọ	≤0.30%
Lapapọ Awọn Aimọ	≤1.50%
Awọn irin Heavy	≤10ppm
Mimọ / Analysis Ọna	≥99.0% (HPLC)
Igbeyewo Standard	Standard Enterprise
Lilo	API, Tyrosine kinase inhibitor receptor

Package & Ibi ipamọ:

Package: Igo, apo apamọwọ Aluminiomu, ilu paali, 25kg / Drum, tabi gẹgẹbi ibeere alabara.

Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina, ọrinrin ati kokoro infestation.

Awọn anfani:

FAQ:

Ohun elo:

Pazopanib Hydrochloride (CAS 635702-64-6) jẹ olona-tyrosine kinase inhibitor ti iṣan endothelial idagbasoke ifosiwewe receptor (VEGFR) -1, VEGFR-2, VEGFR-3, platelet-ti ari idagbasoke ifosiwewe receptor (PDGFR) -a ati - β, fibroblast idagba ifosiwewe receptor (FGFR) -1 ati -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-pato protein tyrosine kinase (Lck), ati transmembrane glycoprotein tyrosine olugba. kinase (cFms).Ni vitro, pazopanib ṣe idiwọ autophosphorylation ligand-induced ti VEGFR-2, Kit, ati PDGFR-beta awọn olugba.Ni vivo, pazopanib ṣe idiwọ VEGF-induced VEGFR-2 phosphorylation ninu awọn ẹdọforo asin, angiogenesis ni awoṣe asin, ati idagbasoke ti diẹ ninu awọn xenografts tumo eniyan ni awọn eku.O ti fọwọsi fun carcinoma sẹẹli kidirin nipasẹ Ounje ati Oògùn AMẸRIKA ni ọdun 2009 ati pe o wa ni tita labẹ orukọ iṣowo Votrient nipasẹ olupese ti oogun naa, GlaxoSmithKline.Votrient jẹ inhibitor kinase ti a tọka fun itọju awọn alaisan pẹlu: 1) carcinoma sẹẹli kidirin to ti ni ilọsiwaju.2) sarcoma asọ ti o ni ilọsiwaju ti o ti gba kimoterapi ṣaaju.